Silexion Therapeutics CORP (SLXN) — SEC Filings
Latest SEC filings for Silexion Therapeutics CORP. Recent 8-K filing on Mar 25, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.
View Silexion Therapeutics CORP on SEC EDGAR
Overview
Silexion Therapeutics CORP (SLXN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 25, 2026: Silexion Therapeutics Corp filed an 8-K on March 25, 2026, specifically under Item 5.02, which typically reports changes in directors or officers and their compensation. While the filing details are not fully provided, the presence of this item suggests potential shifts in leadership or executive pa
Sentiment Summary
Across 2 filings, the sentiment breakdown is: 2 neutral. The dominant filing sentiment for Silexion Therapeutics CORP is neutral.
Filing Type Overview
Silexion Therapeutics CORP (SLXN) has filed 2 8-K with the SEC between Mar 2026.
Recent Filings (2)
-
Silexion Therapeutics Files 8-K on Officer Changes, Compensation
— 8-K · Mar 25, 2026
Silexion Therapeutics Corp filed an 8-K on March 25, 2026, specifically under Item 5.02, which typically reports changes in directors or officers and their comp -
Silexion Therapeutics Files 8-K for Reg FD Disclosure
— 8-K · Mar 24, 2026
Silexion Therapeutics Corp filed an 8-K on March 24, 2026, under Item 7.01, Regulation FD Disclosure, indicating they are making a public announcement of materi
Frequently Asked Questions
What are the latest SEC filings for Silexion Therapeutics CORP (SLXN)?
Silexion Therapeutics CORP has 2 recent SEC filings from Mar 2026, including 2 8-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SLXN filings?
Across 2 filings, the sentiment breakdown is: 2 neutral. The dominant sentiment is neutral.
Where can I find Silexion Therapeutics CORP SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Silexion Therapeutics CORP (SLXN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.